Prestige And Pharmapark Add Bevacizumab To Russia Collaboration

Commercialization Agreement Signed In 2019 Over Herceptin Biosimilar

Russia’s Pharmapark has added Prestige BioPharma’s HD204 biosimilar bevacizumab product to the firms’ commercialization partnership, two years after kicking off the partnership with trastuzumab.

Meeting
The Singapore-based biotech’s HD204 bevacizumab biosimilar is currently undergoing a Phase III clinical study • Source: Shutterstock

Prestige Biopharma has expanded its relationship with Russian biopharma Pharmapark, agreeing exclusive terms for Pharmapark to commercialize in its local market Prestige BioPharma’s biosimilar Avastin (bevacizumab) product, which is currently in Phase III development.

Under the agreement, Prestige BioPharma will supply its product out of its manufacturing facilities in Osong, Korea, with Pharmapark responsible...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.